Clinical studies

IrsiCaixa develop and participate in clinical studies that transfer scientific advances from the laboratory bench to the clinic with the fundamental aim of improving the quality of life of patients.

Coordinator: Dr. Judith Dalmau

Keywords

Research group

Researcher

From date

To date

Clinical response prediction and improvement for intravesical BCG treatment of superficial bladder cancer| BCG-INMUNO-RESP

Principal investigator

Cecilia Cabrera Navarro

Type of study

Prospective pilot study

Start/End

2014

/

2017

Summary and objectives

Bladder cancer incidence in Spain is among the highest in the world and a leading cause of deaths from cancer in men. Initial treatment is transurethral resection, although Bacillus Calmette-Guérin (BCG) immunotherapy has proved to be the local treatment that is most effective in reducing recurrence and limiting progression. Since the exact mechanisms and molecular mediators of tumour control after BCG treatment are unknown, there is no reliable predictor of response. An early marker of response would be invaluable, as it would prevent comorbidities, reduce mortality and avoid the cost associated with ineffective treatment. The study aim is to identify predictors of response to BCG treatment and design new therapeutic strategies.

Research group

Tissue Virology (VITI)
Assaig clínic aleatoritzat, doble cec, controlat amb placebo fase I per avaluar l’efecte immuno-modulador de RUTI® en individus amb carcinoma superficial de bufeta d’alt grau tractats amb Bacillus Calmette-Guerin (BCG) intravesical | RUTIVAC-1

Principal investigator

Cecilia Cabrera Navarro

Start/End

2017

/

2019

Summary and objectives

L’estudi RUTIVAC-1 és un assaig clínic de fase I dissenyat per avaluar la resposta immunològica sistèmica i en mucosa i proporcionar informació de seguretat després de l’administració de RUTI® a individus amb càncer superficial de bufeta d’alt grau.

Research group

Tissue Virology (VITI)